HT
CHRS icon

Headlands Technologies’s Coherus Oncology CHRS Stock Holding History

Headlands Technologies’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$96.9K Sell
69,191
-31,081
-31% -$50.7K 0.01% 662
2026
Q1 		$169K Buy
+100,272
New +$178K 0.02% 614

Other funds holding CHRS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Headlands Technologies's CHRS Position: Q2 2026 in Review

Headlands Technologies reduced its Coherus Oncology (CHRS) stake by 31% in Q2 2026, selling an estimated $50.7K and leaving 69,191 shares worth $96.9K. The position accounts for 0.01% of the portfolio, ranked #662.

Headlands Technologies first reported a position in CHRS in Q1 2026 and has held it in 2 quarters since. The position peaked at $169K in Q1 2026. 146 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

  • Headlands Technologies held 69,191 shares of Coherus Oncology worth $96.9K as of Q2 2026.
  • Headlands Technologies sold 31,081 Coherus Oncology shares in Q2 2026, an estimated $50.7K.
  • Coherus Oncology made up 0.01% of Headlands Technologies's portfolio in Q2 2026, its #662 holding.
  • Headlands Technologies first reported a position in Coherus Oncology in Q1 2026 and has held it in 2 quarters since.
  • Headlands Technologies's Coherus Oncology position peaked at $169K in Q1 2026.
  • 146 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on Headlands Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.